JP2016512198A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512198A5
JP2016512198A5 JP2015561594A JP2015561594A JP2016512198A5 JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5 JP 2015561594 A JP2015561594 A JP 2015561594A JP 2015561594 A JP2015561594 A JP 2015561594A JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5
Authority
JP
Japan
Prior art keywords
independently selected
group
optionally substituted
hydrogen
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561594A
Other languages
English (en)
Japanese (ja)
Other versions
JP6318180B2 (ja
JP2016512198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020700 external-priority patent/WO2014138212A1/en
Publication of JP2016512198A publication Critical patent/JP2016512198A/ja
Publication of JP2016512198A5 publication Critical patent/JP2016512198A5/ja
Application granted granted Critical
Publication of JP6318180B2 publication Critical patent/JP6318180B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561594A 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用 Expired - Fee Related JP6318180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773779P 2013-03-06 2013-03-06
US61/773,779 2013-03-06
PCT/US2014/020700 WO2014138212A1 (en) 2013-03-06 2014-03-05 CaMKII INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2016512198A JP2016512198A (ja) 2016-04-25
JP2016512198A5 true JP2016512198A5 (enExample) 2017-04-06
JP6318180B2 JP6318180B2 (ja) 2018-04-25

Family

ID=51491905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561594A Expired - Fee Related JP6318180B2 (ja) 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用

Country Status (7)

Country Link
US (1) US9951061B2 (enExample)
EP (1) EP2964225B1 (enExample)
JP (1) JP6318180B2 (enExample)
CN (1) CN105517549B (enExample)
AU (1) AU2014225889B2 (enExample)
CA (1) CA2901155C (enExample)
WO (1) WO2014138212A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037106A1 (en) 2014-09-05 2016-03-10 Allosteros Therapeutics, Inc CaMKII INHIBITORS AND USES THEREOF
JP6532737B2 (ja) * 2015-04-01 2019-06-19 東ソー・ファインケム株式会社 ヘテロアセン化合物の製造方法
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
BR112020000258A2 (pt) * 2017-07-06 2020-07-14 Children's Medical Center Corporation composições e métodos para tratar ou prevenir taquicardia ventricular polimórfica catecolaminérgica
BR112020016347A2 (pt) 2018-02-21 2021-01-12 Bristol-Myers Squibb Company Oligonucleotídeos antisense de camk2d e seus usos
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
CN114533701B (zh) * 2020-11-20 2023-12-22 赛灵药业科技集团股份有限公司 一种马钱子碱凝胶贴膏剂及其制备方法和用途
WO2024197267A1 (en) * 2023-03-22 2024-09-26 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof
TW202535878A (zh) * 2023-11-07 2025-09-16 美商卡都瑞恩醫藥公司 吡啶基咪唑並［１，２－ｂ］嗒𠯤之多晶型物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6257798A (en) 1997-01-31 1998-08-25 Board Of Trustees Of The Leland Stanford Junior University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
MXPA04003040A (es) 2001-10-01 2004-07-15 Vanderbil University Uso de inhibidores de calmodulin quinasa ii para tratar la disfuncion miocardica en la enfermedad de corazon estructural.
AU2003300522A1 (en) * 2002-12-27 2004-07-22 Bayer Healthcare Ag 4-phenyl-pyrimido (4,5-b) indole derivatives
US20060057639A1 (en) 2004-06-16 2006-03-16 Pitt Geoffrey S CaMKII/calcium channel phosphorylation-related compositions and methods
US20080255121A1 (en) 2004-11-02 2008-10-16 Dainippon Sumitomo Pharma Co., Ltd. Combination Drug for Treating Autoimmune Disease
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
NZ564065A (en) * 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
EP1896472A1 (de) * 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
EP2161271A1 (en) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2016512198A5 (enExample)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2017534572A5 (enExample)
JP2016538257A5 (enExample)
JP2013545730A5 (enExample)
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
WO2012012347A3 (en) Methods of intravenous administration of glyburide and other drugs
JP2019524897A5 (enExample)
JP2010511701A5 (enExample)
JP2013540114A5 (enExample)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
JP2017524733A5 (enExample)
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP2011518168A5 (enExample)
JP2022523702A (ja) トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
CO6341628A2 (es) \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\"
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2014532751A5 (enExample)
JP2015515496A5 (enExample)
CN106458878B (zh) 2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
ES2531437T3 (es) Docosahexaenoato de pantenilo y su utilización para el tratamiento y la prevención de las enfermedades cardiovasculares
JP4964593B2 (ja) 神経学的病状の治療用のテトラヒドロインドロン誘導体
CN104177324B (zh) 呫吨酮类化合物及其抗抑郁用途